SANOFI-AVENTIS (EPA:SAN) Press Release: FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis
Transparency directive : regulatory news
07/06/2022 22:45
SANOFI-AVENTIS's latest news
17/04/2024 07:00
12/04/2024 20:05
22/03/2024 07:30
15/03/2024 20:04
24/02/2024 15:51
23/02/2024 18:45
23/02/2024 07:00
22/02/2024 19:02
20/02/2024 23:40
15/02/2024 14:00
Other stories
25/04/2024 17:34
25/04/2024 20:31
25/04/2024 19:12
25/04/2024 17:07
25/04/2024 18:44
25/04/2024 18:05
25/04/2024 20:31
25/04/2024 20:52
25/04/2024 19:30
25/04/2024 17:23
25/04/2024 20:11
25/04/2024 19:15
25/04/2024 20:00
25/04/2024 18:59
25/04/2024 13:54
25/04/2024 17:35
25/04/2024 13:48
25/04/2024 19:19
25/04/2024 17:14
25/04/2024 08:13
24/04/2024 09:06
25/04/2024 17:53
25/04/2024 20:44
25/04/2024 18:39
25/04/2024 16:00
25/04/2024 20:17
25/04/2024 19:17
25/04/2024 17:00
25/04/2024 18:48
25/04/2024 14:18
25/04/2024 15:07
25/04/2024 16:15
24/04/2024 11:51
25/04/2024 17:23
Doctor shares red flag symptoms for silent killer cancer that is often mistaken for IBS - The Mirror
24/04/2024 17:35
25/04/2024 06:00
25/04/2024 14:52